| Filed On | Filing |
|---|---|
| 31 Aug 2023 |
8-K/A: Costs Associated with Exit or Disposal Activities
On August 30, 2023, the Compensation and Management Development Committee of the Board of Directors of the Company approved retention benefits for retained employees (other than executive officers) in connection with the Workplace Restru... |
| 12 May 2022 |
8-K/A: Regulation FD Disclosure
PIERIS PHARMACEUTICALS SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY CORPORATE PRESENTATION May 2022 |
| 14 Jan 2022 |
8-K/A: Regulation FD Disclosure
Attached hereto as Exhibit 99.1 and incorporated by reference herein is the November 2021 Investor Presentation of Pieris Pharmaceuticals, Inc. |
Loading...